Standard broth microdilution (with and without bovine serum albumin [BSA] supplementation), tube dilution, and agar dilution susceptibility tests were compared for determining ramoplanin MICs. With a data base of 246 clinical isolates of gram-positive bacteria from 33 U.S. sites, it was shown that (i) agar and tube dilution susceptibility tests gave essentially the same results (93.9% of the test results were within 1 doubling dilution of equivalence), (ii) broth microdilution susceptibility tests gave results up to 5 doubling dilutions higher than agar or tube assays, and (iii) this data skewing could be reversed by BSA supplementation (final concentration, 0.02%) of the broth microdilution test medium.
Ramoplanin (MDL 62, 198 ) is a glycolipodepsipeptide complex with high in vitro activity against gram-positive but not gram-negative bacteria (2) (3) (4) (5) . In this study, we directly compared the National Committee for Clinical Laboratory Standards agar dilution, tube dilution, and broth microdilution susceptibility tests for the measurement of ramoplanin MICs. Because of the reported enhancement of broth microdilution MICs by bovine serum albumin (BSA) supplementation (7), we also added this comparator to our study.
The observed across all species evaluated except for those organisms with which the broth dilution (micro-and tube) assays required fetal bovine serum (5%) supplementation (9 of 11 viridans streptococci and all Leuconostoc spp.). Substitution of 2% lysed horse blood for the fetal bovine serum did not produce the same effect. This skewing was also found to be independent of the ,B-lactam and glycopeptide resistance phenotype of the test organism. The significant variance of ramoplanin broth microdilution and plastic tube MICs from those obtained by glass tube or agar dilution assays has been ascribed to adherence of the antibiotic to plastic, has been shown to be independent of the type of microtiter tray employed, and could be obviated by protein supplementation of the medium (7, 8) . Table 2 shows that 232 (94.3%) of the broth microdilution MICs were 2 or more doubling dilutions lower when the test medium contained a final concentration of 0.02% BSA. The only equivalent MICs in this comparison represented those organisms tested in the presence of 5% fetal bovine serum but not in the presence of 2% lysed horse blood. In contrast, 37.4 and 51.2% of the BSA-broth microdilution MICs were 2 or more doubling dilutions lower than those test quality control data presented here (Table 2 ) and in compilations of MICs for 50 and 90% of strains tested (Table  3) .
In summary, this study confirms and extends earlier observations (7) that showed a marked decrease in ramoplanin broth microdilution MICs when assays were run in proteinsupplemented media. In contrast to these findings, Barry et without BSA supplementation while a tentative breakpoint of . 1.0 ,ug/ml was set for BSA-supplemented broth microdilution and for agar dilution assays. Those data were based on the test population distribution characteristics with susceptibility breakpoints set to include isolates for which the MIC could be 1 doubling dilution greater than that for 99% of the tested strains. In our study, the unsupplemented broth microdilution MICs were 2.0 ,ug/ml for 69.1% of the S. aureus isolates, 40.6% of the coagulase-negative staphylococci, and 30.0% of the enterococci (for one S. aureus isolate, the MIC was 4.0 ,ug/ml). In addition, the tube dilution and agar dilution MICs were 1.0 ,ug/ml for 6.9 and 10.2% of our study population. For none of the test isolates were the MICs above 1.0 ,ug/ml with these techniques, and all BSA-supplemented broth microdilution MICs were .0.5 ,ug/ml. On the basis of these findings, we suggest raising the tentative ramoplanin susceptibility breakpoint to .4.0 ,ug/ml for broth microdilution assays performed without BSA supplementation and to .2.0 ,ug/ml for the remaining susceptibility tests.
